Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
New research shows genomic profiling can detect aggressive prostate cancer not identified at biopsy, while a separate study reveals PTGES3 as a potential therapeutic target for treatment-resistant disease.
